ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference
ClearPoint Neuro (Nasdaq: CLPT), a global therapy-enabling platform company focused on brain navigation and delivery, has announced its participation in the B. Riley Securities 2023 Institutional Investor Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ClearPoint Neuro (Nasdaq: CLPT), a global therapy-enabling platform company focused on brain navigation and delivery, has announced its participation in the B. Riley Securities 2023 Institutional Investor Conference. The company's management team is scheduled to present on Wednesday, May 24, 2023, at 8:15 a.m. Pacific Time.
This conference provides an opportunity for ClearPoint Neuro to showcase its innovative technologies and business strategies to institutional investors. As a leader in brain-focused therapies, the company's presentation is likely to generate significant interest among attendees and potential investors in the medical technology sector.
Details
News Market Reaction – CLPT
The recorded move for CLPT in the trading session of this news was +0.12%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities 2023 Institutional Investor Conference on Wednesday, May 24, 2023 at 8:15 a.m. Pacific Time.
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 65 active sites in the North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 pharmaceutical/biotech companies, academic centers, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
ClearPoint Neuro Contact:
Danilo D’Alessandro, Chief Financial Officer
(949)-900-6833
info@clearpointneuro.com
Caroline Corner, Investor Relations
ir@clearpointneuro.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.